Improvement of trospium-specific absorption models for fasted and fed states in humans.

The purpose of this study was to mechanistically interpret the oral absorption pattern of trospium in fasted and fed states by means of gastrointestinal simulation technology. A drug absorption model was built on the basis of experimental data. According to the generated model, low permeability across the intestinal epithelium, delayed gastric emptying time and a prolonged residence time in the small intestine are the key factors governing trospium absorption in the fasted state. Furthermore, in silico modelling provided a plausible explanation of the pronounced reduction in the oral bioavailability of trospium when administered with food. The simulation results support the decreased dissolution in viscous medium, and the reduced drug permeability in the fed state as the predominant mechanisms for the food effect on trospium absorption.

[1]  G. Amidon,et al.  Ion pairing with bile salts modulates intestinal permeability and contributes to food-drug interaction of BCS class III compound trospium chloride. , 2013, Molecular pharmaceutics.

[2]  M. Harnett,et al.  Study of the Population Pharmacokinetic Characteristics of Once-Daily Trospium Chloride 60 mg Extended-Release Capsules in Patients with Overactive Bladder and in Healthy Subjects , 2013, Clinical Drug Investigation.

[3]  Peter Langguth,et al.  Mechanistic investigation of food effect on disintegration and dissolution of BCS class III compound solid formulations: the importance of viscosity , 2012, Biopharmaceutics & drug disposition.

[4]  Kishore Kumar Hotha,et al.  Determination of the quaternary ammonium compound trospium in human plasma by LC-MS/MS: application to a pharmacokinetic study. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[5]  N. Zinner.  Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder , 2005, Expert opinion on pharmacotherapy.

[6]  U. Fuhr,et al.  Clinical Pharmacokinetics of Trospium Chloride , 2005, Clinical pharmacokinetics.

[7]  U. Fuhr,et al.  Absorption pattern of trospium chloride along the human gastrointestinal tract assessed using local enteral administration. , 2004, International journal of clinical pharmacology and therapeutics.

[8]  Leslie Z. Benet,et al.  Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.

[9]  B Agoram,et al.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.

[10]  H. Merkle,et al.  Intestinal absorption of the quaternary trospium chloride: permeability-lowering factors and bioavailabilities for oral dosage forms , 1997 .

[11]  A. Pfeiffer,et al.  Effect of the quaternary ammonium compound trospium chloride on 24 hour jejunal motility in healthy subjects. , 1994, Gut.

[12]  P. Langguth,et al.  Lipophilisation of hydrophilic compounds. Consequences on transepidermal and intestinal transport of trospium chloride. , 1987, Arzneimittel-Forschung.

[13]  E. Mutschler,et al.  Determination of the bioavailability of the quaternary compound trospium chloride in man from urinary excretion data. , 1986, Arzneimittel-Forschung.